Investigating unclear dyspnoea
Actelion, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has run the PAH Academy since 2004. During this time, they have educated around 3,000 physicians in investigating patients with unclear dyspnoea and diagnosing PAH (Pulmonary Arterial Hypertension) – a rare but lethal disease with high mortality if untreated.
The original program was a mainly non-reusable paper-based 1.5 days workshop. Physicians’ time constraints together with environmental considerations, however, induced Actelion to take the successful academy to the next level. And they asked Symbal to join them.
The solution
Together with editor in chief Björn Kornhall, MD at Department of Cardiology, Skane University Hospital in Lund, Symbal developed an iPad version of the seminar. It can be used in group-learning sessions as well as for individual learning, and follows the diagnostic path from unclear dyspnoea to confirmed diagnosis of e.g. Coronary Artery Disease, Interstitial Lung Disease, Acute Pulmonary Embolism, Chronic Pulmonary Embolism or Pulmonary Arterial Hypertension.
